Mass spectrometry-based proteomics empowers deep profiling of proteome and protein
posttranslational modifications (PTMs) in Alzheimer's disease (AD). Here we review the …

Objective To perform a systematic review and meta-analysis to determine whether fluid and
imaging astrocyte biomarkers are altered in Alzheimer disease (AD). Methods PubMed and …

Our understanding of Alzheimer's disease (AD) pathophysiology remains incomplete. Here
we used quantitative mass spectrometry and coexpression network analysis to conduct the …

Microglial cells consume adenosine triphosphate (ATP) during phagocytosis to clear
neurotoxic β-amyloid in Alzheimer's disease (AD). However, the contribution of energy …

The role of microglia cells in Alzheimer's disease (AD) is well recognized, however their
molecular and functional diversity remain unclear. Here, we isolated amyloid plaque …

The drivers of sporadic Alzheimer's disease (AD) remain incompletely understood. Utilizing
directly converted induced neurons (iNs) from AD-patient-derived fibroblasts, we identified a …

INTRODUCTION The choroid plexus is a secretory epithelial tissue of the central nervous
system (CNS) responsible for cerebrospinal fluid (CSF) production and functions as a barrier …

Neurodegenerative diseases are a growing burden, and there is an urgent need for better
biomarkers for diagnosis, prognosis, and treatment efficacy. Structural and functional brain …

Alzheimer's disease (AD) lacks protein biomarkers reflective of its diverse underlying
pathophysiology, hindering diagnostic and therapeutic advancements. Here, we used …

Molecular chaperones are protective in neurodegenerative diseases by preventing protein
misfolding and aggregation, such as extracellular amyloid plaques and intracellular tau …